25 Years' experience with the Biken Oka strain varicella vaccine a clinical overview

Paediatric Drugs

Volumn 3, Issue 4, 2001, Pages 285-292

  Takahashi, M ^a  

^a Osaka University   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BIKEN VARICELLA VACCINE; CHICKENPOX VACCINE; LIVE VACCINE; UNCLASSIFIED DRUG;

BACTERIAL SUPERINFECTION; BIKEN OKA; CHICKENPOX; CLINICAL TRIAL; DRUG EFFICACY; DRUG TOLERABILITY; ENCEPHALITIS; HUMAN; IMMUNOGENICITY; PNEUMONIA; PRIORITY JOURNAL; REVIEW; VIRUS REACTIVATION; VIRUS STRAIN; VIRUS TRANSMISSION;

EID: 0035038693     PISSN: 11745878     EISSN: None     Source Type: Journal    
DOI: 10.2165/00128072-200103040-00005     Document Type: Review

References (49)

1. Varicella vaccine
2. Prevention of varicella: Updated recommendations of the Advisory Committee on Immunization (ACIP)
3. Varicella: Complications and costs
4. Population-based studies of varicella complications
5. Varicella vaccine
6. Humoral and cellular immune response to varicella-zoster virus in children inoculated with live attenuated varicella vaccine
7. A live varicella vaccine: Its protective effect and immunological aspects of varicella-zoster virus infection
8. Live vaccine used to prevent spread of varicella in children in hospital
9. Recommendations for the use of live attenuated varicella vaccine
10. A live varicella vaccine
11. Oka varicella vaccine is distinguishable from its parental virus in DNA sequence of open reading frame 62 and its transactivation activity
12. Improved identification and differentiation of varicella zoster virus (VZV) and an attenuated varicella vaccine strain using a VZV open reading frame 62-based PCR
13. Development of a live attenuated varicella vaccine
14. Protection against varicella in family contacts by immediate inoculation with live varicella vaccine
15. Varicella vaccine studies in healthy children and adults
16. Post-exposure varicella vaccination in siblings of children with active varicella
17. Application of a live varicella vaccine in children with acute leukaemia or other malignant diseases
18. Application of a live varicella vaccine in children with acute leukemia or other malignancies without suspension of anticancer therapy
19. Protective effect of immediate inoculation of a live varicella vaccine in household contacts in relation to the viral dose and interval between exposure and vaccination
20. Protective efficacy of vaccination in children in four episodes of natural varicella and zoster in the ward
21. Use of a live varicella vaccine to prevent the spread of varicella in handicapped or immunosuppressed children including MCLS (muco-cutaneous lymphonode syndrome) patients in hospitals
22. Studies with live varicella vaccine and inactivated skin test antigen: Protective effect of the vaccine and clinical application of the skin test
23. Spread of varicella in hospitalized children having no direct contact with an indicator zoster case and its prevention by a live vaccine
24. Twenty-year follow-up of protective immunity of the Oka strain live varicella vaccine
25. Varicella vaccine: The Japanese experience
26. Clinical investigation for the severity of breakthrough of varicella among healthy children after immunization with varicella vaccine
27. Experience with live varicella vaccine (Oka strain) in healthy Japanese subjects: 10 year survey at pediatric clinic
28. Clinical and serologic testing of a live varicella vaccine and two-year follow-up for immunity of the vaccinated children
29. Five-year follow-up study of recipients of live varicella vaccine using enhanced neutralization and fluorescent antibody membrane antigen assays
30. Long-term protective immunity of recipients of the Oka strain of live varicella vaccine
31. Modification of chicken pox in family contacts by administration of gamma globulin
32. A five-year immunological follow-up study of the institutionalized handicapped children with live varicella vaccine or infected with natural varicella
33. Chickenpox vaccination of healthy children: Immunological and clinical responses and protective effects in 1978-1982
34. Postlicensure safety surveillance for varicella vaccine
35. A live varicella vaccine in a pediatric community
36. Varicella vaccine: Case studies
37. Effect and follow-up study on varicella vaccine
38. Viral replication and immunologic responses in children naturally infected with varicella zoster virus and in varicella vaccine recipients
39. Contact infection from live varicella vaccine recipients
40. The incidence of herpes zoster
41. The incidence of zoster after immunization with live attenuated varicella vaccine A study in children with leukemia
42. Cost of chickenpox in Canada: Pt I. Cost of uncomplicated cases
43. Cost of chickenpox in Canada: Part II. Cost of complicated cases and total economic impact
44. Cost-effectiveness of a routine varicella vaccination programme for US children
45. Use of live attenuated varicella vaccine to boost varicella-specific immune responses in seropositive people 55 years of age and older: Duration of booster effect
46. Immunisation of the elderly to boost immunity against varicella-zoster virus (VZV) as assessed by VZV skin test reaction